Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions: ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803; Biological · Drug · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions: CMV hyperimmune globulin, Placebo; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions: MESENDO, placebo; Biological · Other
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Human Mesenchymal Stromal Cells, Cell Reconstitution Media; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Sacramento, California • San Francisco, California • Portland, Oregon + 3 more

Conditions: Benign Renal Tumors, Malignant Renal Tumors
Interventions: Laser Tissue Welding Device; Device
Lead sponsor: Laser Tissue Welding, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endothelial Dysfunction
Interventions: Human albumin, Hydroxyethyl starch; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Malaria
Interventions: PfSPZ Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions: Mesenchymal stromal cells, Placebo; Biological · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Acute-On-Chronic Liver Failure
Interventions: SMT + PE-A 5%, Standard Medical Treatment; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor, COlorectal Carcinoma
Interventions: Iodine-124 labeled humanized A33 (antibody); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Community-acquired Pneumonia
Interventions: Trimodulin, Placebo (human albumin 1%); Drug
Lead sponsor: Biotest; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin; Biological · Radiation · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 121
States / cities: Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more

Conditions: Intracerebral Hemorrhage
Interventions: Albumin, Placebo, Brain MRI with and without contrast; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000; Drug · Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Critical Limb Ischemia (CLI)
Interventions: PLX-PAD; Biological
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 45 Years to 99 Years
U.S. locations: 2
States / cities: Clifton, New Jersey • Teaneck, New Jersey

Conditions: Squamous Cell Carcinoma
Interventions: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803; Drug · Biological · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Pancreatic Adenocarcinoma
Interventions: 9-ING-41, Retifanlimab, Gemcitabine, Abraxane; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Fairway, Kansas • Pittsburgh, Pennsylvania

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: IVIG, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 2,416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 1991
U.S. locations: 8
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more

Conditions: Ovarian Cancer
Interventions: Monoclonal antibody hu3S193; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

Endothelial Function After Cardiac Surgery

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

Albumin for Intracerebral Hemorrhage Intervention

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

IVIG - West Nile Encephalitis: Safety and Efficacy

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer